8-K: Terns Pharmaceuticals Reports Promising Q1 2025 Results and Provides Corporate Update

Terns Pharmaceuticals announces its Q1 2025 financial results, highlighting progress in its clinical programs for CML and obesity, with key data readouts expected in Q4 2025.

Summary

• Terns Pharmaceuticals reported its financial results for the first quarter ended March 31, 2025.
• The company is advancing its clinical programs for TERN-701 in chronic myeloid leukemia (CML) and TERN-601 in obesity.
• The dose expansion portion of the Phase 1 CARDINAL trial of TERN-701 has been initiated, with additional safety and efficacy data expected in Q4 2025.
• The Phase 2 FALCON trial of TERN-601 for obesity is enrolling well, with top-line 12-week weight loss data expected in Q4 2025.
• As of March 31, 2025, Terns had $334.3 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2028.
• The net loss for the quarter was $23.9 million, compared to $22.4 million for the same period in 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the progress in clinical trials, encouraging early data, and a strong cash position. However, the increased net loss and G&A expenses temper the overall optimism.

Positives

• TERN-701 demonstrated compelling molecular responses in heavily pre-treated CML patients.
• TERN-701 showed an encouraging safety profile with no dose limiting toxicities.
• The Phase 1 study of TERN-601 demonstrated weight loss over 28 days up to 5.5% with favorable safety and tolerability.
• Terns has a strong cash position of $334.3 million, providing a runway into 2028.

Negatives

• The net loss for the quarter was $23.9 million, which is higher than the $22.4 million loss for the same period in 2024.
• General and administrative expenses increased to $8.7 million from $6.9 million in the same quarter of the previous year.

Risks

• The success of Terns' clinical trials is subject to inherent risks and uncertainties.
• The company's ability to obtain regulatory approval for its product candidates is not guaranteed.
• Unforeseen challenges in patient enrollment or data analysis could delay trial timelines.
• The competitive landscape in oncology and obesity therapeutics could impact the commercial potential of Terns' products.

Future Outlook

Terns anticipates delivering meaningful data from both the TERN-701 and TERN-601 studies in the second half of 2025 and expects its current cash reserves to fund operations into 2028.

Management Comments

• Amy Burroughs, chief executive officer of Terns, stated that Terns had a strong start to 2025, marked by continued excellent execution on its two lead clinical programs.
• Emil Kuriakose MD, chief medical officer of Terns, noted the favorable safety profile and dose-related increase in molecular responses with TERN-701.

Industry Context

Terns is operating in the competitive fields of oncology and obesity, where there is significant unmet need and ongoing innovation. The company is focusing on developing differentiated small-molecule product candidates to address these diseases.

Comparison to Industry Standards

• TERN-701, as an allosteric BCR-ABL inhibitor, is competing with drugs like asciminib (Scemblix) in the CML space; Terns is aiming for improved efficacy and safety.
• TERN-601, as an oral GLP-1 receptor agonist, is competing with injectable GLP-1 RAs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro); Terns is focusing on a competitive weight loss profile, class-leading safety/tolerability, and simple dose titration.
• The 5.5% weight loss over 28 days in the Phase 1 study of TERN-601 is a promising early signal, but needs to be confirmed in the Phase 2 trial against placebo.

Stakeholder Impact

• Positive clinical trial results could benefit shareholders through increased stock value.
• Successful development of new therapies could improve treatment options for patients with CML and obesity.
• Continued operations are supported by a strong cash position, ensuring job security for employees.

Next Steps

• Terns plans to report additional safety and efficacy data from the TERN-701 trial in Q4 2025.
• Terns expects to report top-line 12-week weight loss data from the Phase 2 FALCON trial of TERN-601 in Q4 2025.
• Terns will continue prioritizing its discovery efforts on nominating a GIPR antagonist development candidate.
• Members of Terns senior leadership team will participate in upcoming investor conferences.

Key Dates

Keywords

Terns Pharmaceuticals, TERN-701, TERN-601, CML, Obesity, Clinical Trials, Financial Results, GLP-1, GIPR, THR-beta